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Background and Aims. For distal malignant biliary obstruction in cases with short life expectancy, occlusion of plastic stents (PSs)
does not usually occur before death, and the application of such a procedure is considered adequate from the viewpoint of cost-
eﬀectiveness. Methods and Setting. A new commercially available DLS with side holes, a conventional DLS, and, uncovered self-
expanding metal stents (SEMSs) were retrospectively evaluated in patients with jaundice due to unresectable distal malignant bil-
iary obstruction. Results. A total of 64 patients received endoscopic biliary stenting (23 patients with the new DLS, 24 patients with
conventional DLS, and 17 patients with uncovered SEMS) from December 2002 to August 2009. Median patency time was found
to be 198 days for the new DLS group and 99 days for the conventional DLS group, revealing a signiﬁcant diﬀerence between devi-
ces.Therewas,however,nosigniﬁcantdiﬀerenceinmedianpatencytimebetweenthenewDLSandtheuncoveredSEMS(198days
versus 344 days). Conclusion. The new DLS is eﬃcient and safe and may be considered the ﬁrst choice for unresectable distal malig-
nant obstruction in cases with short life expectancy.
1.Introduction
Endoscopic biliary stenting is a well-established method, and
endoscopic palliation of malignant jaundice can improve pa-
tient quality of life. Two types of biliary stents, each of a
diﬀerent material, are routinely used: plastic stents (PSs) and
self-expanding metal stents (SEMSs), and it is necessary for
each stent to be appropriately selected for each case.
SEMSs have a longer patency period than plastic stents.
However, uncovered SEMSs (UMSs) also have several draw-
backs, including higher cost, irretrievability once placed, and
susceptibilitytotumorovergrowthandingrowth,whichmay
result in stent dysfunction [1].
PSs on the other hand are less expensive and remain a
popular alternative to metallic stents. Their major drawback,
however, is their propensity to clog, often necessitating re-
peated stent changes in order to maintain biliary drainage
[2]. To prolong the duration of PSs patency, a double-layer
stent (DLS; Olympus Medical Systems, Tokyo, Japan) has
been developed and shown to be superior to regular PSs with
respect to patency and is consequently being used more fre-
quently than PSs [3]. When bending of the malignant bile
duct is advanced, the tip of the stent impacts the biliary wall,
and since the stent has an oriﬁce only in the tip, this situation
leads to an early occlusion of DLS and becomes a major issue
[3, 4]. To handle this issue appropriately, we modiﬁed the
DLSwithtwoholes(18gauge)ontheproximalsideofthetip
(Figure 1) and found that bile duct impaction was reduced
and stent patency was low. The new DLS was authorized for
use under the Pharmaceutical Aﬀairs Act in April 2010.
Therefore, we retrospectively analyzed the eﬃcacy and the
safety of this new, commercially available stent.
2.Subjects
A total of 64 obstructive jaundice patients with unresectable
malignant lower biliary obstruction received endoscopic bil-
iary stenting (EBS) at the Toho University Omori Medical2 Diagnostic and Therapeutic Endoscopy
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Figure 1: DLS with side holes (Olympus Medical Systems, Tokyo, Japan). Two side holes (18-gauge size) on the proximal side of the tip.
Center (Table 1). Endoscopic retrograde cholangiopancre-
atography (ERCP) was performed using a large channel
(4.2mm, 3.7mm) duodenoscope (Olympus TJF-260V/TJF-
240,JF-260V;OlympusMedicalSystems).Endoscopicsphin-
cterotomy (EST) was routinely performed before stent inser-
tion. After EST, a 7.2Fr endoscopic nasobiliary drainage
(Hanaco Medical Co., Saitama, Japan) or 7Fr PSs (Zimmon
type biliary stent; Wilson-Cook Medical, Winston-Salem,
NC) was temporarily inserted. After conﬁrming an impro-
vement of serum total bilirubin (<3mg/dL)level,aconven-
tional DLS, new DLS, or UMS was inserted.
With regardto the UMSgroup, because we experienced a
case in 2001 in which covered SEMSs (CMS) exhibited mig-
ration, UMS has since been used for malignant lower biliary
obstruction. For UMS, a Zilver stent (Wilson-Cook Medical)
was inserted because of its very low axial force values [5].
We gave priority to placing DLS for distal malignant
biliary obstruction cases with short life expectancy from
December 2002. Because a severely bending bile duct impac-
ted on the proximal stent oriﬁce in a manner similar to that
ofbileductinvasion,thestenthadtobereplacedafterashort
time due to its short patency period. There were however
cases of severely bending bile duct due to bile duct invasion,
forwhichwehadto replaceDLSbecausethe proximal side of
DLS was in contact with the bending bile duct. Accordingly,
we gave priority to placing uncovered SEMSs from February
2004.To improvetheplastic stent,weselectedthenew modi-
ﬁed DLS with two holes on the proximal side and gave
priority to placing the new DLS from January 2005 to
September 2009.
Chemotherapywasperformedinallcases,exceptinthose
that were expected to have poor prognosis within three
months, elderly cases, and cases of low performance status.
For cases of unresectable pancreatic cancer, gemcitabine
(GEM) was administrated in a standard manner (drip infu-
sion of 1000mg/m2 a tas t a b l es p e e d )o n c ep e rw e e kf o r
three consecutive weeks, with a one-week interval between
courses. After conﬁrming a decrease of 3.0mg/dL in serum
Table 1: Patient characteristics by stent type and laboratory values
on admission.
New DLS DLS UMS
Number 23 24 17
Gender (m/f) 16/7 19/5 9/8
Age 68.1 ± 12.8 70.9 ± 11.2∗1 72.1 ± 11.2∗2
Diagnosis
Pancreatic cancer
III 2 4 2
IVa 6 6 7
IVb 11 11 4
Biliary duct cancer 0 0 2
Other 4 3 2
Unresectable due to:
Advanced stage 21 20 13
Patient age 0 4 2
Other 2 0 2
Chemotherapy
+1 6 1 1 8
− 71 3 9
T-Bil (mg/dL) 6.8 ± 5.6 5.2 ± 4.6∗1 6.6 ± 7.4∗2
ALP (IU/L) 1027 ± 515 1296 ± 890∗1 1094 ± 910∗2
∗1New DLS+ versus DLS n.s. ∗2New DLS versus UMS n.s.
total bilirubin level, GEM was started. If adverse events
occurred, administration of GEM was postponed or its dose
was reduced [6, 7]. Chemotherapy for the metastasis group
was based on the primary disease. Adverse eﬀects were
evaluated following the National Cancer Institute Common
Terminology Criteria for Adverse Events ver. 3.0 (CTCAE)
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3. ExaminationItems
Obstruction periods, causes of obstruction, complications
related to stent insertion, and the status of GEM administra-
tion in cases of malignant lower biliary obstruction were
examined. Informed consent was obtained from all patients.
This study was conducted following approval by the institu-
tional review board of our hospital.
4. Exclusion Items
A history of biliary surgery, accidental symptoms related to
ERCP, and endoscopic percutaneous or surgical drainage, as
well as papilla cancer, were determined as exclusion items.
Moreover, the patients in the conventional DLS group that
was investigated in the Japanese Multicenter Randomized
Trial of Endoscopic Stenting for nonresection pancreatic
head cancer (JM-TEST [9]) from October 2005 to October
2007 were also excluded.
5.StatisticalAnalysis
Statistical analysis was performed using SPSS for Windows,
version 11.0J (SPSS Inc., Chicago, IL). All continuous vari-
ables are presented as mean ± standard error. A P value of
<0.05 was considered statistically signiﬁcant. Comparisons
of the outcome variable (stent clogging) were analyzed using
the chi-square test or Fisher exact test. The cumulative clog-
ging-free survival period was compared across the study
groups using the Kaplan-Meier method, and diﬀerences in
the patency rates were analyzed using the log-rank test. In
addition, the eﬀect of stent type on clogging-free survival
was analyzed by constructing age-adjusted (≥65 years old)
and sex-adjusted Cox proportional hazard regression models
with simultaneous introduction of covariates. For all analy-
ses, patient data were censored at the time of stent clogging
or death, as well as at stent migration.
The primary endpoint was the interval between stent
insertion and the ﬁrst episode of clogging or migration, or
the presence of jaundice at death without stent exchange.
6. Results
Followup data until death or stent occlusion were obtained
from all new DLS and conventional DLS UMS participants.
Theperiodfrominsertiontoobstructionwasconsideredun-
censored while the period from insertion until death without
obstruction was considered censored.
In the case of distal malignant biliary obstruction, med-
ianpatencytimewas198daysforthenewDLSgroup,99days
for the conventional DLS group, and 344 days for the UMS
group, and a signiﬁcant diﬀerence was noted (log-rank test;
P = 0.0014; Figure 4). In the GEM group, the median pat-
ency time was 245 days for the new DLS group and 95 days
fortheconventionalDLSgroup,344daysfortheUMSgroup,
and signiﬁcant diﬀerence was noted (log-rank test; P =
0.0058; Figure 5). In the non-GEM group, the median pat-
ency time was 127 days for the new DLS group, 100 days for
the conventional DLS group, and 139 days for the UMS
Table 2: Incidence of stent malfunction.
DLS (24) New DLS (23) UMS (17)
Mean patency time 74 ± 66 160 ± 136∗1 196 ± 147∗3
Stent malfunction 16 15∗2 7∗3
(%) (66.6) (65.2) (41.1)
Ingrowth 0 0 4
Overgrowth 2 1 0
Sludge 5 3 0
Food scraps 2 4 1
Impaction
(bile duct) 330
Impaction
(duodenal wall) 311
Other 1 3 1
Complication 3 2∗2 0∗3
(%) (12.5) (8.7) (0)
Cholecystitis 2 0 0
Pancreatitis 1 0 0
Hemorrhage 0 0 0
Migration 0 1 0
Other 0 1 0
DLS versus new DLS: ∗1P<0.05. ∗2n.s. UMS versus new DLS: 3n.s.
group, and no signiﬁcant diﬀerence was noted (log-rank test;
P = 0.179; Figure 5).
Table 2 shows the incidence of stent malfunction. Mean
followupwas 160±136 daysforthenewDLSgroupand 74±
66 days for the conventional DLS group (P = 0.015). No
diﬀerence was observed in terms of early stent malfunction
(15 side-hole DLSs versus 16 conventional DLSs; P = 0.580).
Bile duct impaction was found in 3 side-hole DLS patients
after 71, 90, and 187 days, and in 3 conventional DLS pa-
tients after 10, 14, and 22 days. Cholecystitis was found in 2
conventional DLS patients after 3 and 38 days. Stent migra-
tion was found in 1 new DLS patient with metastatic lym-
phadenopathy,andcholangitisoccurred198daysafterplace-
ment. ERCP revealed stent migration, and the stent was re-
moved by balloon catheter (Multi3, Olympus Medical Sys-
tems) deﬂation (Figure 2). In one patient, side-hole DLS ﬂap
damage on the duodenal side was seen 97 days after place-
ment (Figure 3). Results are summarized in Table 2.
Regarding incidence of stent malfunction, the diﬀer-
ence between the new DLS group and the UMS group
was not signiﬁcant (Table 2). Furthermore, univariate anal-
ysis revealed no signiﬁcant diﬀerences for nonobstruction
factors (Table 3).
7. Discussion
Patients with inoperable malignant obstruction of the distal
bile duct can be palliated by endoscopic biliary stenting in
up to 95% of cases, with a mortality rate of 2% [10, 11].
The mean life expectancy of these patients is short, and to4 Diagnostic and Therapeutic Endoscopy
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Figure 2: ERCP shows malfunctioning DLS migration at 198 days after placement.
Proximal side
Distal side
Figure 3: New DLS ﬂap damage at 97 days after placement.
improvequalityoflife,apalliativestentshouldideallyremain
patent until death. Although polyethylene, Teﬂon, and poly-
urethane are often used for PSs, no diﬀerences in patency
have been found [12, 13]. During the past decade, many
randomized clinical trials have been conducted with the goal
of optimization stent design. Although smoothness of the
stent wall has been considered an important factor for stent
function, no detailed quality analysis of the commercially
available stents used in the various trials has been performed
[13–15]. It has been reported, however, that the presence of
side holes increases the amount of sludge in PSs, and there-
fore, improved TANNENBAUM type stents do not have such
side holes.
Coene et al. showed that prostheses without side holes
exhibited signiﬁcantly lower sludge deposition when com-
pared with those with side holes [13]. Consequently, Seitz et
al. demonstrated the eﬃcacy of the 10Fr. Teﬂon straight stent
(e.g., TANNENBAUM stent) without side holes by showing
its signiﬁcantly extended patency [13, 16]. Additional studies
havefoundnosigniﬁcantadvantageinstentpatencybetween
TANNENBAUM and standard polyethylene stents [17, 18].
To overcome the stent patency problem, the DLS was devel-
oped and comprised an inner layer of perﬂuoroalkoxy (PFA)
containing specially processed and chemically smoothed
Teﬂon,andtheresultsofatrialshowedthatDLShadalonger
patency period than standard polyethylene stents (with sideDiagnostic and Therapeutic Endoscopy 5
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Figure 4: Patency period in malignant lower biliary obstruction with new DLS, conventional DLS, and UMS. Signiﬁcant diﬀerence was
noted using the new DLS (log-rank test; P = 0.0014).
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Figure 5: Stent patency in malignant lower biliary obstruction with chemotherapy. Chemotherapy group (a); 245 days for the new DLS
group, and 95 days for the conventional DLS group, 344 days for the UMS group (log-rank test; P = 0.0058). Nonchemotherapy group (b);
127 days for the new DLS group, 100 days for the conventional DLS group, and 139 days for the UMS group (log-rank test; P = 0.179).
holes) [19], although, in several cases of advanced bending
of the bile duct, DLS of the proximal tip was found to be
impacted on the bile duct wall, and this situation was sus-
pected to be responsible for the reduced patency period.
Nevertheless, the factor (Teﬂon or absence of side holes) that
contributes most to favorable outcome remains unknown.
Sung et al. showed in a randomized trial that polyethylene
stents both with and without side holes perform equally well
[20]. Recently, Van Berkel et al. compared polyethylene and
Teﬂon Amsterdam-type stents in a randomized trial and
could not ﬁnd any diﬀerence in patency [21]. The com-
bination of Teﬂon material and the absence of side holes6 Diagnostic and Therapeutic Endoscopy
Table 3: Risk factors for stent occlusion by univariate analysis.
HR
(95% CI) P
Age (>65 versus
65 years)
0.951
(0.637–1.419) 0.507
Gender 0.910
(0.600–1.380) 0.427
Pancreatic cancer
stage
1.348
(0.904–2.011) 0.100
IVb chemotherapy
group
0.945
(0.651–1.370) 0.483
DLS 0.938
(0.647–1.359) 0.476
New DLS 0.877
(0.609–1.262) 0.341
UMS 1.286
(0.789–2.097) 0.205
CI: conﬁdence interval; HR: hazards ratio.
results in superior patency rates, whereas omitting side holes
in the design of a polyethylene stent or the use of Teﬂon
materialinaconventionaldesigndoesnotimprovestentpat-
ency. Although the results of such clinical studies are con-
tradictory, they emphasize that the smoothness of the stent
surface is of great importance, either as a result of omitting
side holes or by using material with a low friction coeﬃcient.
T h u s ,m a n yt r i a l sh a v eb e e nu n d e r t a k e ni na ne ﬀort to dec-
rease the rate of clogging in plastic biliary stents. In these
studies, the eﬀectiveness of diﬀerent stent materials and
designs (with and without side holes, coated and uncoated)
has been evaluated [17, 20–22]. A number of studies have
shown that SEMSs have longer patency and lower occlusion
rates than conventional PSs [1, 23–27]. CMSs have been
developed recently to prevent tumor ingrowth and have
shown a longer patency period than that of conventional
UMSs [28–30]. Isayama et al. conducted a prospective ran-
domized study of covered (handcrafted) versus uncovered
diamond stents for the management of distal malignant
biliary obstruction. The covered diamond handcraft stent
prevented tumor ingrowth and was superior to the uncov-
ered stent for the treatment of patients with distal malignant
biliary obstruction [31, 32]. UMS has a self-expansive, metal
wire mesh structure. Although cholecystitis and pancreatitis
are rare, tumor ingrowth is a feared complication of both
conditions, and while CMS might prevent tumor ingrowth,
there is still a concern that the SEMSs covering the mem-
brane might obstruct the pancreatic or cystic ductoriﬁces,
resulting in acute pancreatitis or cholecystitis. Additionally,
various studies have shown the eﬀectiveness of endoscopic
removal of CMS using a snare [33]. Advanced bending of
the bile duct and biliary obstruction near the papilla appears
as inward migration. A recent study showed that uncovered
WallstentsandcoveredWallstentsmadenodiﬀerencetostent
patency.BecauseofconsecutiveinwardmigrationusingCMS
in our department in 2001, we utilized UMS for subsequent
cases of malignant biliary obstruction [34, 35]. In cases with
short life expectancy (4–6 month or less), such as those with
advancedpancreaticcancer,occlusionofPSsdoesnotusually
occur before death, and application of PSs is considered ade-
quate from the viewpoint of cost-eﬀectiveness [23, 25, 36–
38].
The ﬁndings of this retrospective study revealed that
because the conventional DLS and new DLS are made of the
same materials and have the same shapes, only the presence
orabsenceofsideholesinthenewDLScanberesponsiblefor
prolonging stent patency. Coene et al. also emphasized that
whensideholesarerequiredinplasticstentstooptimizepro-
ximal obstructions, their construction must be improved to
ensureminimalinnerwallirregularity.Therefore,wefocused
oninnerwallsmoothnessandalongerpatencyperiodforthe
DLS [13].
The new DLS structure is the same as that of the conven-
tional DLS, which has an inner layer made of PFA containing
specially processed and chemically smoothed Teﬂon. The
inner surface is smooth and does not undulate, which pre-
vents the stent from becoming encrusted and clogged with
biliary constituents or proteins [3, 4, 9].
In addition, the new DLS is modiﬁed with side holes.
Although the previous side-hole stents had only one hole
(3mm) at both ends of the endoprosthesis, the new DLS has
two holes (18 gauge) on the proximal side. The additional
side hole may aﬀect the patency period.
Moreover, this clinical study showed that the diﬀerence
between new DLS and uncovered SEMSs had no eﬀect on
stent patency. New chemotherapeutic agents such as GEM
are more eﬀective for pancreatic cancer, and the survival
time has improved [39]. In addition to its overall anticancer
eﬀects, stent patency should be prolonged by the suppres-
sion of tumor ingrowth and overgrowth. Stent occlusion
may necessitate postponement of GEM administration and
requires additional intervention or hospitalization which
leads to deterioration of the patient’s quality of life. Possible
inﬂuences of GEM on the patency of stents are prolongation
of patency by controlling the tumor mass and shortening of
patency by clogging following biliary infection. It is expected
that patients who undergo GEM will have a longer stent
patency than those in non-GEM groups. The signiﬁcance of
stent patency maintenance is much greater than before as it
can eliminate readmission due to stent occlusion and post-
ponement of GEM. Further development of eﬀective chemo-
therapy will further extend the signiﬁcance of longer stent
patency, and consequently, the selection of stents should be
reassessed from this point of view.
Although various stents have been developed, simple
stent placement and exchange, stent patency for more than
sixmonths,andlow-pricedstentsareﬁnallyavailable.There-
fore,whenstartingchemotherapy,wesuggestthenewDLSas
the ﬁrst-choice option.
This retrospective study showed the eﬃcacy and safety
of the new DLS with side holes, which is characterized by a
high-cost-beneﬁtratioandmaybeconsideredtheﬁrstchoice
for unresectable distal malignant biliary obstruction in cases
with short life expectancy. However, further studies includ-
ing cost-beneﬁt assessment and a randomized, prospective
comparison trial with side-hole DLS and CMS need to be
conducted. To establish the clinical eﬃcacy of the new DLS,Diagnostic and Therapeutic Endoscopy 7
weplantoconductaprospectivestudyofnewtheDLSversus
the covered wall stent.
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